Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Jazz Pharmaceuticals ( (JAZZ) ).
On July 8, 2025, Jazz Pharmaceuticals announced the appointment of Renee Gala as the new President and Chief Executive Officer, effective August 11, 2025. This leadership change follows a robust succession process and marks a significant milestone in the company’s long-term succession planning. Bruce Cozadd, the current CEO, will retire on September 12, 2025, but will continue as Chairperson of the Board. Gala, who has been with Jazz since 2020, has played a pivotal role in the company’s transformation and growth, and her appointment is expected to drive further value creation and sustainable growth for Jazz Pharmaceuticals.
The most recent analyst rating on (JAZZ) stock is a Buy with a $200.00 price target. To see the full list of analyst forecasts on Jazz Pharmaceuticals stock, see the JAZZ Stock Forecast page.
Spark’s Take on JAZZ Stock
According to Spark, TipRanks’ AI Analyst, JAZZ is a Outperform.
Jazz Pharmaceuticals achieves a balanced stock score with strong financial management and promising neuroscience growth. While technical signals are neutral and valuation is moderate, strategic R&D efforts and acquisitions offer growth potential. Key risks involve debt management, oncology challenges, and potential tariff impacts.
To see Spark’s full report on JAZZ stock, click here.
More about Jazz Pharmaceuticals
Jazz Pharmaceuticals plc is a global biopharmaceutical company headquartered in Dublin, Ireland, focused on developing life-changing medicines for serious diseases with limited or no therapeutic options. The company has a diverse portfolio of marketed medicines, including therapies for sleep disorders, epilepsy, and cancer treatments, and is committed to pioneering research and development in oncology and neuroscience.
Average Trading Volume: 989,783
Technical Sentiment Signal: Strong Sell
Current Market Cap: $6.6B
Find detailed analytics on JAZZ stock on TipRanks’ Stock Analysis page.